AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18471454
Drug: Niacin extended
RxNorm normalized name: Niacin Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin extended release plus simvastatin (NER/S) 1,000/20 mg/day
Trial: 18471454
Drug: Niacin extended
RxNorm normalized name: Niacin Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin extended release plus simvastatin (NER/S) 2,000/20 mg/day
Trial: 16936391
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 20 mg/day for 2 weeks followed by 10 mg/day for 2 weeks
Trial: 14657842
Drug: Oral antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antihistamines
Trial: 10690544
Drug: Treatment-induced minimum
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-induced minimum NSE values
Trial: 10690544
Drug: Etoposide and
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide and cisplatin treatment (4 to 6 cycles)
Trial: 10431879
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin
Trial: 3884406
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg 3 times daily orally)
Trial: 27094495
Drug: Neurodynamic mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodynamic mobilization group (manual therapy and neurodynamic techniques)
Trial: 27094495
Drug: Electrophysical modalities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysical modalities group (red and infrared laser and ultrasound therapy)
Trial: 24428467
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg orally once daily) plus sofosbuvir (400 mg orally once daily) for 12 or 24 weeks, with or without ribavirin
Trial: 18408224
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + reduced-dose interferon (IFN) 6 or 3 MIU
Trial: 18408224
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + reduced-dose IFN
Trial: 6617242
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg indapamide + methyldopa (average 1100 mg daily)
Trial: 6617242
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide + methyldopa (average 1575 mg daily)
Trial: 6617242
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg indapamide (Step 1 medication only)
Trial: 6617242
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg indapamide (Step 1) and 50 mg hydrochlorothiazide (Step 1)
Trial: 31806127
Drug: Conventional prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional prophylactic antibiotic treatment
Trial: 31806127
Drug: Incremental prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental prophylactic antibiotic treatment
Trial: 22315048
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (80 mg caffeine)
Trial: 17161119
Drug: Levonorgestrel 90
RxNorm normalized name: LEVONORGESTREL 90 ug / ETHINYL ESTRADIOL 20 ug ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 90 μg/ethinyl estradiol 20 μg daily for 1 year
Trial: 15753500
Drug: Fast group
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast group (1 mL/sec)
Trial: 15753500
Drug: Slow group
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow group (0.05 mL/sec)
Trial: 12224975
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (TAC) (20 mg/mL)
Trial: 12224975
Drug: Intralesional 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 5-fluorouracil (5-FU) (50 mg/mL)
Trial: 12224975
Drug: Intralesional TAC
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional TAC (1 mg/mL) mixed with 5-FU (45 mg/mL)
Trial: 9690971
Drug: Newer antipsychotic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antipsychotic drugs (clozapine, risperidone, olanzapine, amisulpride, quetiapine, sertindole)
Trial: 9690971
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic drugs (haloperidol, chlorpromazine)
Trial: 7750167
Drug: Chinese and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese and western medicine treatments
Trial: 3383542
Drug: minibag via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minibag via gravity flow (MG)
Trial: 3383542
Drug: minibag with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minibag with secondary infusion tubing below a volumetric infusion pump (MP)
Trial: 3383542
Drug: metered chamber
RxNorm normalized name: HOLDING CHAMBER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metered chamber via volumetric infusion pump (MC)
Trial: 28830365
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate infusion (25 ml/kg, approximately 2 l over 30 min)
Trial: 23325710
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of triamcinolone acetonide (TA)
Trial: 21830063
Drug: ivabradine (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (5-7.5 mg bid) plus bisoprolol 5 mg od
Trial: 21830063
Drug: bisoprolol uptitrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol uptitrated to 7.5 mg and then 10 mg od
Trial: 17126776
Drug: Transdermal nitroglycerine
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerine (3-in, 7.5 cm)
Trial: 14506196
Drug: (131)I-trace-labeled BsMAb
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I-trace-labeled BsMAb doses escalated from 10 to 100 mg/m(2)
Trial: 14506196
Drug: 75 mg/m(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/m(2) BsMAb and 2.6-4.2 GBq of (131)I-hapten
Trial: 14506196
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of BsMAb dose to 40 mg/m(2)
Trial: 7914795
Drug: Ro 40-2148
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40-2148 (400 mg diluted in 100 ml water, twice a day for 14 days)
Trial: 3196390
Drug: Emepronium 25
RxNorm normalized name: emepronium 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium 25 mg/kg p.o.
Trial: 3196390
Drug: Emepronium 50
RxNorm normalized name: emepronium
DrugBank: Emepronium (DB13505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium 50 mg/kg p.o.
Trial: 3196390
Drug: Emepronium 100
RxNorm normalized name: emepronium 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium 100 mg/kg p.o.
Trial: 3196390
Drug: Emepronium 200
RxNorm normalized name: emepronium 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium 200 mg q.i.d. in human volunteers
Trial: 3196390
Drug: Emepronium 400
RxNorm normalized name: emepronium
DrugBank: Emepronium (DB13505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emepronium 400 mg q.i.d. in human volunteers
Trial: 25272149
Drug: EPA-enriched n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-enriched n-3 1000 mg/d
Trial: 25272149
Drug: DHA-enriched n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched n-3 1000 mg/d
Trial: 16934909
Drug: SGN-15 200
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-15 200 mg/m2/week with docetaxel 35 mg/m2/week (Arm A)
Trial: 16934909
Drug: Docetaxel 35
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 35 mg/m2/week alone (Arm B)
Trial: 9266922
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (200 mg of iron sucrose)
Trial: 8493761
Drug: Human interferon
RxNorm normalized name: Human interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human interferon alpha (HuIFN‐alpha) administered orally
Trial: 16724169
Drug: Extended-release oxybutynin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin, 10 mg daily
Trial: 16724169
Drug: Extended-release tolterodine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine, 4 mg daily
Trial: 6206316
Drug: Indapamide (IND)
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide (IND) 2.5 mg q am
Trial: 6206316
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 50 mg q am
Trial: 26879816
Drug: Artemisinin conventional
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin conventional formulation (160 mg)
Trial: 26879816
Drug: Artemisinin conventional
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin conventional formulation (500 mg)
Trial: 26879816
Drug: Artemisinin micronized
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin micronized formulation (160 mg)
Trial: 26879816
Drug: Artemisinin micronized
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin micronized formulation (160 mg) with piperaquine phosphate (360 mg)
Trial: 26879816
Drug: Increasing dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose of artemisinin
Trial: 14700510
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (amlodipine 5 mg + benazepril 20 mg)
Trial: 14700510
Drug: Benazepril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (40 mg)
Trial: 10333347
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg
Trial: 12473867
Drug: hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (HCTZ) 25 mg
Trial: 9440779
Drug: Immunotherapy using
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy using standardized D. farinae antigen
Trial: 2776953
Drug: Intracervical gel
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical gel containing 50 mg 17 beta‐oestradiol
Trial: 768851
Drug: L-asparaginase 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase 100 U/kg
Trial: 768851
Drug: L-asparaginase 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase 500 U/kg
Trial: 768851
Drug: L-asparaginase 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase 1500 U/kg
Trial: 768851
Drug: L-asparaginase (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase (all doses)
Trial: 30963552
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (ferric carboxymaltose)
Trial: 30963552
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (ferrous sulphate)
Trial: 25720104
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (continuous negative pressure of -80 mmHg)
Trial: 21086117
Drug: Zolpidem (Zp)
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem (Zp) 10 mg
Trial: 21086117
Drug: Zopiclone (Zc)
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zopiclone (Zc) 7.5 mg
Trial: 10889149
Drug: Omeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, amoxicillin, and clarithromycin (OAC) for 1 week; n = 295
Trial: 8737958
Drug: trimetazidine 20
RxNorm normalized name: trimetazidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimetazidine 20 mg tid
Trial: 8737958
Drug: propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 40 mg tid
Trial: 1568427
Drug: Steroid electrode
RxNorm normalized name: ELECTRODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid electrode (0.5 mg dexamethasone)
Trial: 1568427
Drug: Electrode without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrode without steroid
Trial: 1568427
Drug: Steroid electrode
RxNorm normalized name: ELECTRODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid electrode
Trial: 2860153
Drug: Intraperitoneal irrigation
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal irrigation with low molecular weight povidone-iodine solution (PVP-I LMW)
Trial: 30539285
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 1g
Trial: 30539285
Drug: Topical fibrin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fibrin sealant (FS) 10 ml
Trial: 27986480
Drug: vonapanitase 10
RxNorm normalized name: Vonapanitase
DrugBank: Vonapanitase (DB11690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonapanitase 10 μg
Trial: 27986480
Drug: vonapanitase 30
RxNorm normalized name: Vonapanitase
DrugBank: Vonapanitase (DB11690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonapanitase 30 μg
Trial: 17695214
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of cyclamate and 22.5 mg of saccharine
Trial: 15147226
Drug: Alcohol gel
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol gel as an adjunct to handwashing
Trial: 15147226
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (alcohol gel with handwashing)
Trial: 8087484
Drug: Mechanical injection
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical injection
Trial: 8087484
Drug: Hand injection
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand injection
Trial: 2675668
Drug: Succinylcholine injected
RxNorm normalized name: succinylcholine Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine injected at different speeds (20 mg/s, 8 mg/s, 4 mg/s, 2 mg/s, 1 mg/s)
Trial: 788751
Drug: Oral indoramin
RxNorm normalized name: indoramin
DrugBank: Indoramin (DB08950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral indoramin
Trial: 788751
Drug: Intravenous indoramin
RxNorm normalized name: indoramin
DrugBank: Indoramin (DB08950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous indoramin
Trial: 26461821
Drug: Crisaborole topical
RxNorm normalized name: crisaborole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole topical ointment, 2%
Trial: 9400905
Drug: Acebutolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (100 mg twice daily)
Trial: 9400905
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg slow-release twice daily)
Trial: 26468478
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg twice daily)
Trial: 8101300
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 mg twice daily)
Trial: 8101300
Drug: Aspirin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50 mg per day)
Trial: 8101300
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (desired prothrombin time range 2.8-4.8 international normalised ratio)
Trial: 6875209
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (400 mg/day for one month)
Trial: 24401481
Drug: Ologen™ implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ologen™ implant (OLO)
Trial: 17503753
Drug: Dietary uridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary uridine supplement (36 g three times a day for 10 consecutive days/month)
Trial: 15474756
Drug: E2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 levels >= 20 pmol/l
Trial: 15474756
Drug: E2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 levels < 20 pmol/l
Trial: 10776469
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Trial: 10776469
Drug: Cefuroxime (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (750 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Trial: 10776469
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg i/v post operatively, 12 hourly for 2 days followed by oral 500 mg twice daily for 3 days), n = 35
Trial: 10776469
Drug: No antibiotic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic, n = 30
Trial: 1655220
Drug: Edatrexate (10‐EdAM)
RxNorm normalized name: edamine
DrugBank: Ethylenediamine (DB14189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edatrexate (10‐EdAM) 80 mg/m2, Cyclophosphamide 800 mg/m2, Cisplatin 80 mg/m2 on day 1, repeated every 3 weeks
Trial: 1655220
Drug: Edatrexate (10‐EdAM)
RxNorm normalized name: edamine
DrugBank: Ethylenediamine (DB14189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edatrexate (10‐EdAM) 70 mg/m2, Cyclophosphamide 700 mg/m2, Cisplatin 70 mg/m2 on day 1, repeated every 3 weeks
Trial: 1655220
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose schedule
Trial: 6304513
Drug: Interferon-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (3 X 10(6) units intramuscularly before transplant, then three times a week for six weeks and twice a week for eight weeks, total of 102 X 10(6) units)
Trial: 20025679
Drug: Low-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose i.v. iron therapy (LD-IVIT) - <or=50 mg/week of iron sucrose
Trial: 20025679
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron therapy (OIT)
Trial: 20025679
Drug: Low-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose i.v. iron therapy (LD-IVIT)
Trial: 16542286
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg infusion every 6 h
Trial: 16542286
Drug: CIM 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIM 400 mg infusion every 12 h
Trial: 16542286
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg infusion every 12 h
Trial: 12767502
Drug: Intrathecal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal triamcinolone acetonide (TCA) administration (6 administrations every third day)
Trial: 12767502
Drug: Continued intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued intrathecal TCA treatment (1 injection every 6 to 12 weeks)
Trial: 9379341
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin 20 mg/m2/day i.v. for 3 days and etoposide 100 mg/m2/day i.v. for 3 days)
Trial: 9379341
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus melatonin